RNA Sequencing Market Growth Outpacing Conventional Techniques 2030
RNA sequencing has emerged as an indispensable tool in unraveling the intricacies of the cell transcriptome, providing crucial insights into differential gene expression. Over the past decade, RNA sequencing has witnessed a remarkable surge in adoption, outpacing conventional microarray-based techniques and Sanger sequencing methods. With its broader coverage and unparalleled resolution capabilities, RNA sequencing is poised to maintain a significant presence in the biotechnology market. The exponential growth in research grants allocated to next-generation sequencing (NGS)-based RNA sequencing projects is expected to fuel the expansion of the global RNA sequencing market further. Its increasing relevance in cancer research and agricultural studies continues to be a driving force behind market growth. As novel applications like spatial transcriptomics and precision medicine gain prominence, the adoption of RNA sequencing is projected to flourish in the coming years.
Read More Insights: https://www.fairfieldmarketresearch.com/report/rna-sequencing-market
Expression Profiling Reigns Supreme in RNA Sequencing Applications
The advent of sequencing technology has ushered in a new era of direct, long-read RNA sequencing, complemented by innovative computational tools. These advancements are contributing to the rapid expansion of the RNA sequencing market. Among the various sequencing technologies, sequencing by synthesis is likely to be the preferred choice among end-users. Expression profiling is expected to remain the dominant application, primarily due to the rising incidence of metabolic disorders, multiple sclerosis, and other related conditions. Gene mutations, leading to abnormal or inadequate protein production, are responsible for over 7,000 distinct types of rare and genetic diseases, affecting approximately 80% of the estimated 400 million individuals worldwide with rare diseases, according to Global Genes.
Expression profiling plays a pivotal role in diagnostics and specific treatment options for chronic disorders, ensuring sustained demand in the long term. However, despite its preference over conventional sequencing methods for its high sensitivity to gene expression, high throughput capabilities, and quantifiability, the substantial initial capital investment remains a significant challenge to wider adoption of RNA sequencing.
Cancer Research Community’s Enduring Interest in RNA Sequencing
The remarkable progress achieved by RNA sequencing methods in recent decades highlights their enormous potential for application in research and therapeutics. From bulk RNA sequencing to single-molecule, single-cell, and spatial transcriptomics, this approach is delivering high-resolution insights into individual cells with unparalleled accuracy. RNA sequencing has been instrumental in oncology research over the past decade, offering invaluable insights into cancer evolution, differential gene expression analysis, biomarker discovery, and immunotherapy. RNA sequencing has the potential to address oncology drug resistance, a major obstacle in cancer treatment, by providing a deeper understanding of the mechanisms involved. This could be a critical step toward the development of precision medicine for cancer, offering new possibilities for cancer prevention, diagnosis, and treatment.
Recent Developments in RNA Sequencing
Recent research has highlighted the potential benefits of RNA sequencing in exploring new therapeutic avenues for liver cancer, one of the most common and deadly malignancies worldwide. The method has shown promise in enhancing our understanding of the disease’s metabolism, as demonstrated in a study conducted in July 2021.
In July 2021, scientists at the US-based St. Jude Children’s Hospital published groundbreaking findings on the application of RNA sequencing in pediatric cancer patients. The study highlighted how RNA sequencing, in combination with whole exome sequencing, could enable precision medicine applications for pediatric cancer patients, potentially saving lives.
North America Leads the Way in RNA Sequencing Adoption for R&D
North America has consistently dominated the global RNA sequencing market, and this trend is expected to persist due to the region’s increasing acceptance of RNA sequencing techniques. With a growing number of RNA sequencing grants and improved reimbursement coverage for diagnostics, the market is set to thrive in the long term. The development of personalized medicine, especially in the United States, will further bolster the market’s performance. Substantial R&D investments and external funding worldwide are also supporting the market’s expansion, as governments recognize the urgent need for genomics research in the face of rising cancer and rare disease prevalence, with the latter primarily being genetic in nature.
About Rare Diseases and RNA Sequencing
Rare diseases have a significant impact on global healthcare, with approximately 3-10% of all hospitalizations related to rare diseases, affecting individuals of all ages. Tragically, 65% of rare diseases are associated with reduced lifespans. The diagnosis of rare diseases often takes between six and eight years, adding to the urgency of advancing research in this area. According to Rare Diseases International and EURORDIS, rare diseases affect 3.5% – 5.9% of the global population at any given time, with 72% of these diseases having a genetic basis, and the majority of them manifesting in childhood.
Key Players in the Global RNA Sequencing Market
The global RNA sequencing market boasts several prominent players contributing to its promising growth prospects. Leading companies in the market include Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann La-Roche AG, Merck KGaA, BGI, Fluidigm Corporation, Oxford Nanopore Technologies, Lexogen GmbH, Pacific Biosciences, Becton, Dickinson and Company, QIAGEN N.V., Dolomite Bio, Takara Bio Inc., PerkinElmer Inc., Eurofins Scientific, Tecan Genomics, Inc., GENEWIZ, Inc., Hamilton Company, Macrogen, and Zymo Research.
QIAGEN N.V. introduced a range of innovative RNA sequencing library preparation solutions for NGS in October 2011. In June 2017, Agilent Technologies announced a strategic agreement with Agendia to develop a version of the latter’s RNA sequencing kit for inclusion in Agilent’s portfolio.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 – By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/rna-sequencing-market
Visit Our Blogs:
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
